August 30, 2016 11:49 PM ET

Biotechnology

Company Overview of Melinta Therapeutics, Inc.

Company Overview

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

300 George Street

Suite 301

New Haven, CT 06511-6663

United States

Founded in 2000

42 Employees

Phone:

203-624-5606

Fax:

203-624-5627

Key Executives for Melinta Therapeutics, Inc.

Chief Executive Officer and Director
Age: 56
President and Chief Operating Officer
Compensation as of Fiscal Year 2016.

Melinta Therapeutics, Inc. Key Developments

Melinta Therapeutics Appoints Eugene Sun as Chief Executive Officer and Member of the Board of Directors

The Board of Directors of Melinta Therapeutics announced that Eugene Sun, M.D. has been appointed Melinta’s Chief Executive Officer and member of the Board of Directors, making permanent the role he has filled in an interim capacity since September 2015. Sun most worked recently as Corporate Vice President, Global Pharmaceutical Clinical Development.

Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer

Melinta Therapeutics appointed John Temperato as President and Chief Operating Officer. Prior to joining Melinta, John led the sales and managed markets division of Salix Pharmaceuticals. He played a critical role at Salix in the successful commercialization and growth of Xifaxan. Prior to Salix, John held positions at Celltech Pharmaceuticals, where he was responsible for managed market strategy, Medeva Pharmaceuticals and Adams Laboratories.

Melinta Therapeutics, Inc. Presents at The 23rd Annual Future Leaders in the Biotech Industry conference, Mar-11-2016 11:30 AM

Melinta Therapeutics, Inc. Presents at The 23rd Annual Future Leaders in the Biotech Industry conference, Mar-11-2016 11:30 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, Room 508, New York, New York, United States. Speakers: Eugene Sun, Interim Chief Executive Officer and Executive Vice President of Research & Development.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Melinta Therapeutics, Inc., please visit www.melinta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.